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Abstract
The beneficial effect of a microencapsulated feruloyl esterase producing Lactobacillus fermentum ATCC 11976 formulation
for use in non-alcoholic fatty liver disease (NAFLD) was investigated. For which Bio F1B Golden Syrian hamsters were fed a
methionine deficient/choline devoid diet to induce non-alcoholic fatty liver disease. Results, for the first time, show
significant clinical benefits in experimental animals. Examination of lipids show that concentrations of hepatic free
cholesterol, esterified cholesterol, triglycerides and phospholipids were significantly lowered in treated animals. In addition,
serum total cholesterol, triglycerides, uric acid and insulin resistance were found to decrease in treated animals. Liver
histology evaluations showed reduced fat deposits. Western blot analysis shows significant differences in expression levels
of key liver enzymes in treated animals. In conclusion, these findings suggest the excellent potential of using an oral
probiotic formulation to ameliorate NAFLD.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is a potentially severe
condition that comprises a spectrum of conditions characterized
by vesicular fatty change in the liver in the absence of excessive
alcohol consumption [1]. NAFLD is associated with increased
central adiposity, triglycerides (TG), uric acid, insulin resistance,
hyperlipidemia and low levels of high-density lipoprotein (HDL)
[2,3]-. NAFLD prevalence estimates in the general population
range from 17–33%, and increases to 100% in the obese
population [1]. Other than lifestyle and diet modifications, there
is no universally proven treatment [4,5]. The only available
recommendation is avoidance of hepatotoxins and aggressive
management of associated co-morbid conditions.
Probiotic bacteria are live microorganisms which confer health
benefits when administered in adequate amounts [5–14]. These
microorganisms need to survive harsh factors encountered in the
gastro-intestinal tract and be viable in high concentrations to
bestow health benefits on the host. Microencapsulation in
specialized ultra-thin semi-permeable polymer membranes has
been successfully shown to protect live bacterial cells in oral and
other delivery applications [14–18].
Ferulic acid [4-hydroxy-3-methoxycinnamic acid] (FA) is
considered a potential chemotherapeutic agent as it has the
capacity to lower cholesterol and exhibits anti-oxidant associated
protective effects [19,20]. Feruloyl esterase (FAE) causes the
hydrolytic release FA from its bound state in most foods (bran
cereals, whole grain products, fruits, vegetables, tea, coffee, wine
and beer). FAE activity is commonly found in microorganisms in
the rumen and in different bacterial genera present in the human
and animal gut [21]. FA can be released from its fibre-bound state
by the human intestinal microbiota. The presence of FAE activity
has been demonstrated in the large intestine of rats and humans
and is largely responsible for the release and bioavailability of FA
in mammals [22–25]. Although there is a partial released of
dietary fibre-bound FA by colon micro-organisms, the concentra-
tion of the released FA is too low to act as a chemopreventive
agent [26,27]. Because the intestinal FAE is very likely the major
route for the release of FA in vivo, the site and levels of this
enzyme are critical factors influencing the bioavailability of FA.
The presence of FAE activity, able to release antioxidant
compounds that can be absorbed in the gut [28], was therefore
used as a specific criterion for the selection of the probiotic
microorganism.
We have previously studied the activity of known FAE-
producing lactic acid bacteria, and selected Lactobacillus fermentum
ATCC 11976 because of its strong FAE activity [29]. This
probiotic was then employed to show that oral ingestion of FAE
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producing microencapsulated lactic acid bacteria increases avail-
ability of FA via supplementation of FAE in the gut [18,30]. The
lipid lowering and antioxidant properties of FA therefore depend
on its availability for absorption, the concentration of the released
FA and its subsequent interaction with target tissues [19,20,26].
In a previous study we have used a computer-controlled
simulated human GI model that closely mimics in vivo conditions.
Microencapsulated FAE-producing bacterial cells were shown to
increase their viable counts and the ability to de-esterify feruloyl
ester over a 10 hour period under simulated intestinal conditions,
after passing through the acidic stomach environment [30].
Another study evaluated the effect of oral administration of the
FAE-producing strain L. fermentum CRL1446 on the intestinal FAE
activity and oxidative status in Swiss albino mice. The determi-
nation of basal FAE activity levels in non-treated mice showed that
this activity was mainly located in intestinal mucosa, being similar
in the small and large intestine [21]. Their results showed that the
effect of L. fermentum CRL1446 administration on intestinal FAE
activity was time and dose dependent. The authors speculated that
not only might L. fermentum CRL1446 supply exogenous FAE
enzymes into the gut, it could stimulate the FAE activity of colonic
microbiota via an indirect effect. They further hypothesized that L.
fermentum CRL1446 could also stimulate the FAE activity of
epithelial cells. Nevertheless, FAE induction mechanisms in the
gut have not yet been elucidated.
The present research, for the first time, investigates the potential
of orally delivered, microencapsulated FAE producing natural
Lactobacillus fermentum ATCC 11976 bacterial cells in the manage-
ment of NAFLD in pharmaceutically acceptable formulations.
Materials and Methods
Bacterial growth media and chemicals
EFA (ethyl ferulate; ethyl 4-hydroxy-3-methoxycinnamate),
PLL [poly(L-lysine)] and CaCl2 were purchased from Sigma–
Aldrich Canada (Oakville, ON, Canada). Commercially available
sodium alginate (A2158), extracted from a brown alga [the giant
kelp (Macrocystis pyrifera)] was obtained from Sigma–Aldrich
Canada. Its viscosity at 2% (w/v) and at 25uC is ,250 cP (mPa?s).
According to the supplier, the alginate comprises approximately
61% mannuronic acid and 39% guluronic acid and has a
molecular mass ranging from 12 to 80 kDa. MRS (De Man–
Rogosa–Sharpe) broth was obtained from Difco (Sparks, MD,
U.S.A.). The water was purified with an EASYpure Reverse
Osmosis System and a NANOpure Diamond Life Science (UV/
UF) ultrapure water system from Barnstead/Thermoline (Dubu-
que, IA, U.S.A.). All other chemicals were purchased from
commercial sources and were of analytical or HPLC grade.
Bacterial strains and culture conditions
L. fermentum ATCC 11976 is a known FA-producing bacterium
from Cedarlane Laboratories (Burlington, ON, Canada). The
bacterium was stored, cultured and microencapsulated in alginate-
poly-l-lysine-alginate semi-permeable microcapsules (MWCO 60–
70 kDa), as follows. The bacterial culture was stored refrigerated
in Difco’s MRS medium containing 30% (v/v) glycerol at 280uC
and serially propagated three times in fresh MRS medium before
experimental use. L. fermentum ATCC 11976 was then cultivated in
MRS-EFA broth [MRS supplemented with 10% (w/v) EFA in
DMF (dimethylformamide)]. A 1% (v/v) inoculum was used, and
incubations were performed at 37uC for 20 h under microaero-
philic conditions (5% CO2).
Microencapsulation of bacterial cells and their
enumeration
Microencapsulation was carried out with 36-h-old cultures of
the bacteria grown in MRS-EFA broth by using an Inotech
encapsulator (Inotech Biosystems International, Rockville, MD,
U.S.A.). The cultures were centrifuged at 7000 g for 20 min at
15uC. The supernatant was decanted off. The pelleted CWW (cell
wet weight) was resuspended in PS [physiological saline (0.9% (w/
v) NaCl)], pooled and gently added to 60 mL of a lightly stirred
sterile 1.8% (v/v) sodium alginate solution. Encapsulation
parameters were kept constant: (cell load, 4.17 g CWW/100 ml
of alginate; nozzle diameter, 300 mm; vibration frequency,
918 Hz; syringe pump speed, 9.64 ml/min; voltage, 1.5 kV; and
current 2 A). The beads were allowed to gel for 5 min in a gently
stirred sterile CaCl2 solution (0.1 M), followed by a wash with PS.
It was consequently coated for 10 min with 0.1% (w/v) sterile PLL
followed by a wash with PS. A final coat of 0.1% (w/v) sterile
alginate for 10 min followed, trailed by a final wash with PS.
Bacteria-free empty capsules were prepared as controls. This
procedure was performed in a Microzone Biological Containment
Hood (Microzone, Ottawa, ON, Canada) to assure sterility. The
microencapsulated lactobacilli were stored in minimal solution
(10% (v/v) MRS and 90% (v/v) PS) at 4uC until further use. The
bacterial numbers of the Lactobacillus strain in the microcapsules
were determined by plate counts on MRS agar. The bacteria were
pour-plated at the end of the refrigerated storage time. For each
bacterium, storage fluid was aspirated; the microcapsules were
crushed and resuspended in 0.9 mL of PS. Samples were serially
10-fold diluted in diluent. Triplicate plates were inoculated with
0.5 mL samples from the appropriate dilutions and incubated
under 5% CO2 at 37uC for 72 h. The microcapsules contained, on
an average, 1011 cfu (colony-forming units)/mL of bacteria.
Morphological studies by microscopic analysis revealed that the
mean capsule diameter was 602630 mm for both empty and
bacteria-loaded capsules and the encapsulated bacterial cells
appeared to be evenly distributed within the membrane.
Animals, diet and NAFLD
Male Bio F1B Golden Syrian hamsters, 8 weeks old (BioBree-
ders, MA, USA) with an average body weight of 90 g were housed
in a climate-controlled space with inversed, alternating light and
dark cycles (12:12-hr light– dark cycle; lights on at 19:00). All
experimental protocols complied with the Animal Care Commit-
tee of McGill University and Canadian Council on Animal Care
guidelines. The animals were acclimatized for 2 weeks before the
start of the experiment. They were fed commercial rodent ration
(LabDietH Rodent Laboratory Chow 5001, Purina Laboratories,
St. Louis, MO, USA) and water. Baseline values of serum total
cholesterol (TC) were determined at the end of acclimatization
from 14-hour food-deprived hamsters. These values were used to
randomize animals into treatment groups. NAFLD was induced in
hamsters, as described previously [31]. Briefly, the animals were
fed a synthetic, purified hyperlipidemic methionine-deficient and
choline-devoid diet (Purina Laboratories, St. Louis, MO) for 5
weeks, following a switch to a semi-purified hyperlipidemic
methionine-adequate and choline-deficient diet (Purina Labora-
tories, St. Louis, MO, USA) [31].
Experimental protocol
To investigate the therapeutic efficacy of the formulation,
animals in the treatment group (n = 12 per group) were orally
gavaged 1 mL of microcapsule formulation (L. fermentum ATCC
11976 cells at 11.51 log cfu/mL) twice daily and the control group
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(n = 12) with empty microcapsules, for 12 weeks, using 18G/
50 mm with 2.25 mm ball diameter stainless steel gavage needles.
Diet consumption and body weight were monitored. Fasting blood
samples were collected every 14 days via the saphenous vein. The
hamsters were euthanized by CO2 asphyxiation and blood was
withdrawn by cardiac puncture. The whole liver was excised and
flash frozen in liquid nitrogen.
Metabolite identification using mass spectrometry
25 mL of serum was diluted using 20% (v/v) methanol to a
volume of 1 mL. Mass spectra were recorded on a Finnigan LCQ
DUO ion trap mass spectrometer (Fisher Scientific, Ontario,
Canada) using electrospray (ESI) in the positive mode. The ion-
spray voltage was maintained at 4.5 KV, nitrogen was used as the
nebulising sheath gas and the heated capillary temperature was
kept at 200uC and scanning from mass 50 to 500.
Histology analysis
Cryopreserved livers were ultra-sectioned (4–5 mm thickness),
stained for fat with ORO and examined under light microscopy.
Coded histologic slides of livers were scored for fat infiltration
using MATLAB (The MathWorks, Inc., MA, USA) as follows: no
visible fat: score 0; up to 10% of liver surface infiltrated by fat:
score 1; 10% to 30% fat: score 2; 30% to 50% fat: score 3; and
.50% fat: score 4. Infiltration was classified as micro-vesicular,
macro-vesicular, or mixed.
Determination of key proteins in liver cholesterol
metabolism
Liver tissue was lysed, homogenized and the supernatant was
processed for extraction of hepatic lipids and proteins, according
to the procedure previously described [32]. The sample was
analyzed for levels of 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase, cholesterol 7a-hydroxylase (CYP7A1),
acyl-CoA cholesterol acyltransferase-1 and -2 (ACAT-1 and
ACAT-2) and carboxyl ester lipase (CEL). Protein concentration
from the liver extract and serum was determined by RC DC
Protein Assay (Bio-Rad Laboratories, CA, USA). Abundance in
the liver extract and the serum concentration of lecithin
cholesterol acyltransferase (LCAT) was determined by Western
blot. HMG-CoA reductase goat polyclonal antibody (1:100), goat
polyclonal anti-CYP7A1(1:200), goat polyclonal anti-LCAT anti-
bodies (1:200) from Santa Cruz Biotechnology (Santa Cruz, CA,
USA), rabbit polyclonal anti-ACAT-1(1:500) (Novus Biologicals,
Littleton, CO, USA), rabbit polyclonal anti-ACAT-2 (1:100)
(generously provided by Professor Lawrence L. Rudel, Depart-
ment of Biochemistry and Comparative Medicine, Wake Forest
University, Winston-Salem, NC.) and goat polyclonal anti-CEL
(1:200) (Santa Cruz Biotechnology) were used as primary
antibodies. The Western blots were quantified using ImageJ 1.40
(Rasband, W.S., ImageJ, U. S. National Institutes of Health,
Bethesda, MD, USA, http://rsb.info.nih.gov/ij/, 1997–2008).
Clinical chemistry analysis
Serum lipids (TC, HDL cholesterol and TG), glucose, uric acid
and C-reactive protein (CRP) and liver function tests for albumin,
ALT, aspartate transaminase (AST), alkaline phosphatase (ALP)
and Gamma glutamyl transpeptidase (GGT) were assayed using a
Hitachi 911 clinical chemistry autoanalyzer (Roche Diagnostics,
USA) with reagent kits from Roche Diagnostics (Laval, QC,
Canada). Serum free cholesterol (FC) and non-esterified fatty acids
(NEFA) were estimated using kits (Wako Chemicals USA, Inc.
VA).
Serum insulin was measured by an Enzyme Immunoassay from
SpiBio (Massy, France). Fasting plasma insulin and glucose were
used to calculate insulin resistance from the homeostasis model
assessment for insulin resistance (HOMA-IR) [(fasting glucose *
fasting insulin)/22.5] [33].
Hepatic TC, FC, TG, NEFA and phospholipid concentrations
were determined enzymatically. Hepatic and serum esterified-
cholesterol (EC) concentrations were calculated as the difference
between TC and FC concentrations. Total hepatic lipid content
was calculated as the sum of FC, EC, TG, NEFA and
phospholipids. Total neutral lipids were determined as the sum
of FC, EC, TG and NEFA.
Statistical analysis
Statistical Analysis System (SAS Enterprise Guide 4) (SAS
Canada, ON) was used for statistical analysis. Data are presented
as mean 6 standard deviation (s.d.). One- way analysis of variance
(ANOVA) or Student’s t test were used to compare mean
differences between the control and the experimental groups, as
appropriate. Differences between variables were considered
significant at a 95% confidence interval (P,0.05).
Results
Metabolite identification using mass spectrometry
Each spectrum was obtained from the end-point serum of the
animals. ESI analysis in positive mode was shown as sensitive to
the metabolites of interest. Molecular ions of three known
metabolites of FA were searched for [34]. The molecular ion
[M+1]+ detected in the treatment group sera was 371 in the MS
spectrum, correlating to the addition of a glucuronic acid (m/z
176) to FA (m/z 194). No free or conjugated forms of FA were
detected in control animal sera, as shown in Figure 1.
Liver histology
Figure 2A and 2B show photomicrographs of liver histology
representing the lipid distribution of hamsters administered
microencapsulated L. fermentum ATCC 11976 for 12 weeks. As
expected, fatty liver changes were detected in all animals with
hepatocytes comprising micro-vesicles filled with small, fine fat
droplets and centrally-placed nuclei. Macro-vesicles, obscuring the
nucleus by displacement to the periphery of the cell were present
in only two of twelve control hamsters along with concomitant
micro-vesicles. The degree of fatty change, evaluated as fatty
infiltration scores, was significantly lowered in the treated hamsters
(P = 0.0028). The score decreased from 2.460.50 in the controls to
1.860.50 in the treated group (Table 1).
Key metabolic enzymes
Results, in Figure 3, show hepatic tissue HMG-CoA reductase
levels in the group treated with microencapsulated L. fermentum
ATCC 11976, 30.7% lesser than that in control animals
(P = 0.027). Furthermore, no significant difference was found in
hepatic CYP7A1 protein levels between the treated and control
animals. Consequently, the HMG-CoA reductase-to-CYP7A1
ratio, reflecting the balance between cholesterol synthetic and
catabolic capacities, was markedly decreased in the treatment
group. The treated group showed a significant down-regulation of
ACAT-1 (51.1%) compared to the control group (P = 0.043). On
the other hand, liver levels of ACAT-2 were virtually identical in
both groups. Liver CEL levels were more elevated in the control
than the treated hamsters (82.1% down-regulation) (P = 0.014).
Data in Figure 3 shows a significant difference (63.4%) in serum
Probiotic Ameliorates NAFLD
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Figure 1. ESI+– MS spectrum of hamster serum. (A) control animals (B) animals treated with microencapsulated L. fermentum ATCC 11976. The
decisive molecular ion [M+1]+ detected, only in the treatment group sera, was 371 in the MS spectrum, correlating to the addition of a glucuronic acid
(m/z 176) to FA (m/z 194).
doi:10.1371/journal.pone.0058394.g001
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LCAT levels between the treated and control hamsters
(P = 0.0048).
Hepatic lipids
Results in figure 4, show a significant lowering effect of the gross
liver weight in treated animals (3.9160.39 g/100 g body weight)
compared to control animals (4.6360.25 g/100 g body weight)
(P,0.0001). Animals receiving microencapsulated L. fermentum
ATCC 11976 had a significant reduction in total liver lipid
concentrations (80.10613.17 mmol/g liver), compared to control
animals (99.75611.41 mmol/g liver) (P = 0.001).
Examination of the liver lipid-extract revealed that about 80%
of the total hepatic lipids were neutral lipids, while the rest
comprised phospholipids. The treated group had total neutral
lipids of 64.48610.78 mmol/g liver, significantly lower than the
control group (80.9868.55 mmol/g liver) (P = 0.0006). The
decrease in neutral liver lipids affected mostly the hepatic
cholesterol and triglyceride levels. Free and esterified cholesterol
concentrations were 3.5261.66 and 7.6063.93 mmol/g liver in
treated animals and 6.1161.90 and 12.2562.79 mmoles/g liver,
respectively in controls (P = 0.0022 and P = 0.0039, respectively).
The triglyceride concentration was 12.8563.27 mmol/g liver
tissue in treated animals, compared with 16.8763.69 mmol/g
liver in controls (P = 0.011).
While the probiotic formulation decreased triglyceride and
cholesterol concentrations in treated hamsters, the effects on non-
esterified fatty acids were less (P = 0.14). The hepatic phospholipid
content of the treated hamsters (15.6263.57 mmol/g liver) was
significantly less than the controls (18.7763.21 mmol/g liver)
(P = 0.038). A greater accumulation of hepatic neutral lipids and
phospholipids in the control animals was observed compared to
treated animals (Figure 4).
End-point fasting serum metabolites
At the experimental end-point, significant differences were
observed in serum TC, HDL, EC, NEFA, uric acid and serum
fasting insulin, with a decrease in HOMA-IR in treated animals as
compared to the control group (Table 2). Furthermore, serum FC,
TG, glucose and CRP levels were not significantly different
between the two groups (Table 2).
Liver Function Tests
The liver function test results are shown in Table 3. Total serum
albumin, AST and ALP of hamsters was not affected by treatment
with microencapsulated L. fermentum ATCC 11976 (P.0.05). On
the other hand, ALT and GGT values were significantly lower
(P,0.05) for the hamsters treated with the probiotic formulation
as compared to the control animals.
Discussion
This study evaluated the efficacy and investigated the potential
mode(s) of action of microencapsulated L. fermentum ATCC 11976
Figure 2. Representative photomicrographs of livers from hamsters after 12 weeks. (A) with microencapsulated L. fermentum ATCC 11976
treatment and, (B) without treatment. Microencapsulated L. fermentum ATCC 11976-supplemented animals (A) show lesser fat infiltration in the
hepatocytes whereas, control animals (B) are filled with 30% greater micro-vesicular fat deposits (Oil Red O, 400X).
doi:10.1371/journal.pone.0058394.g002
Table 1. Histological fatty-liver scores of hamsters fed hyperlipidemic diet without and with treatment with microencapsulated L.
fermentum ATCC 11976.
Hamsters, 12 Weeks on hypercholesterolemic, hyperlipidemic diet
Score Control animals (n = 12)
Animals treated with microencapsulated L.






Mean Score 6 SD 2.460.5 1.860.5
doi:10.1371/journal.pone.0058394.t001
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to reduce cholesterol accumulation in the liver of hamsters with
diet-induced NAFLD.
FA, in conjugated form, is continuously introduced into
circulation due to metabolic activities of the bacterial formulation.
From there, it is distributed to the liver and other tissues to exert
beneficial effects. FA is rapidly excreted via the urine but the
conjugated FA metabolite is secreted into bile and enters the
enterohepatic circulation [35]. This may prolong FA and FA-
metabolite bioavailability, explaining the presence of glucuronide
metabolite in the serum of fasted, treated animals (Figure 1). The
absence of corresponding metabolites in the serum of control
hamsters is evidence of active FAE in the GI tract (Figure 1).
Oral feeding of the microencapsulated probiotic effectively
reduced fat infiltration in the liver, despite continuous feeding of a
high-fat, high-cholesterol diet. Hepatic-fat lowering was attributed
to the redistribution of lipid depots in the body rather than
intestinal mal-absorption of fat. Although liver weight was
significantly reduced in treated hamsters, no histopathological
signs of inflammation or tissue damage were observed. The data
suggests that a higher level of metabolic impairment of fatty acid
oxidation may exist in control hamsters. In the liver itself, lipid
(cholesterol, triglyceride and phospholipid) metabolism was altered
due to bacterial metabolism. The major decrease in hepatic
neutral lipids was observed in the cholesterol fraction, whereas the
proportion of TG remained stable and NEFA significantly
increased. FC accumulation in the mitochondria, but not TG
and NEFA, is known to sensitize hepatocytes to cytokine-induced
apoptosis and disease progression [36]. The probiotic formulation
is thus thought to reduce cholesterol augmentation in the
mitochondria and restore antioxidant levels, offering some
Figure 3. Western blot and group data depicting key hepatic and serum cholesterol metabolism protein abundance in liver of
hamsters fed a high-cholesterol high-fat diet, without (control) and with microencapsulated L. fermentum ATCC 11976
supplementation. n = 12. * P,0.05.
doi:10.1371/journal.pone.0058394.g003
Figure 4. Pre-clinical efficacy of microencapsulated L. fermentum ATCC 11976 on hepatic neutral lipids and phospholipids in
hamsters. n = 12. * P,0.05.
doi:10.1371/journal.pone.0058394.g004
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protection from liver damage. The increased neutral lipids and
NEFA in the control animal livers is consistent with decreased
oxidative capacity, creating favorable conditions for the ‘‘second
hit’’ which may cause progression to severe NAFLD stages.
The decrease in liver cholesterol of treated hamsters can be
related to the changes in key liver proteins. The reduction in liver
HMG-CoA reductase may be due to regulation of feedback
control of cholesterol synthesis mechanisms that operate during
cholesterol supplementation. The comparatively higher expression
of hepatic ACAT-1 in the control group may account for the
elevated hepatic EC content, as its main function is to prevent the
accumulation of free cholesterol within cell membranes by
conversion to cytoplasmic lipid droplets [37,38]. In contrast, levels
of ACAT-2, which play a role in hepatic packaging, production,
and secretion of very low density lipoproteins (VLDL) [37], were
unchanged. Typically, expression of CYP7A1 is augmented by
increased free-cholesterol in hepatocytes [39]. In this study,
unchanged hepatic CYP7A1 levels and reduced hepatic HMG-
CoA reductase were associated with a 42% reduction in the
relative ratio of HMG-CoA reductase-to-CYP7A1. CEL is the key
enzyme required for releasing free cholesterol from intracellular
esterified cholesterol storage when cellular-free cholesterol levels
are depressed [37]. LCAT deficiency may have disrupted the
reverse-cholesterol transport pathway and, consequently, a reduc-
tion in either abundance of serum HDL cholesterol, the particle
distribution of HDL or the lipid composition of circulating
lipoproteins [40].
The unchanged rate of cholesterol depletion, owing to
continued secretion of VLDL particles, bile acids and biliary
cholesterol (normal levels of ACAT-2 and CYP7A1), and the
relative reduction of cholesterol synthesis and storage due to down-
regulation of HMG-CoA reductase and ACAT-1, may have
caused a paucity of free cholesterol in the cellular pool of the liver.
This suggests that up-regulation of CEL may be a compensatory
response to decreased hepatic tissue FC concentrations. Since
CEL was up-regulated, the stored cholesteryl esters may have been
de-esterified to increase available FC as substrate for CYP7A1,
accounting for the decrease in fat content of the treated hamster
livers. Export and catabolism of the liver cholesterol was thus
shown to exceed import and synthesis in the livers of treated
animals.
In NAFLD, when adipose tissue becomes resistant to insulin,
serum lipoprotein levels alter, and influx of NEFA to the liver
increases, diverting fatty acids into storage rather than secretion
[40]. When storage increases, the intra-hepatic NEFA become
more amenable to lipid peroxidation whose by-products can
impair mitochondrial function and promote hepatic inflammation
[36,40]. In the presented study, the NEFA content of the treated
hamster liver did not significantly change, whereas the serum of
treated hamsters showed a significant reduction in NEFA. The
predominant increased flux of fatty acids in NAFLD may occur
Table 2. Serum metabolite levels in hamsters gavaged empty capsules (control) and microencapsulated L. fermentum ATCC 11976
(treatment).
Hamsters, 12 Weeks on hypercholesterolemic, hyperlipidemic diet
End-point serum metabolites Unit
Control animals, Empty
capsules (n = 12)
Animals treated with microencapsulated L.
fermentum ATCC 11976 (n = 12) P-value
TC mmol/L 23.1868.74 14.3368.25 0.024
HDL mmol/L 2.6560.16 1.6760.21 0.0001
FC mmol/L 1.5561.13 1.7161.08 0.76
EC mmol/L 21.9469.79 12.9168.69 0.033
TG mmol/L 8.3661.75 6.2863.37 0.095
NEFA mmol/L 3.3360.89 2.6560.42 0.029
Glucose mmol/L 14.2165.98 15.4164.36 0.59
Insulin ng/mL 1.4060.79 0.5960.35 0.0042
doi:10.1371/journal.pone.0058394.t002
Table 3. Liver function tests in hamsters gavaged empty capsules (control) and microencapsulated L. fermentum ATCC 11976
(treatment).
Hamsters, 12 Weeks on hypercholesterolemic,
hyperlipidemic diet
Parameter Reference Range Unit
Control animals, Empty
capsules (n = 12)
Animals treated with
microencapsulated, L. fermentum
ATCC 11976 (n = 12) P-value
Albumin 35–55 g/L 40.33616.61 30.8865.67 0.079
ALT 7–56 U/L 80.46653.94 28.40626.86 0.022
AST 5–35 U/L 35.93612.42 55.29621.49 0.130
ALP 20–126 U/L 82.3668.30 82.28632.06 0.990
GGT 8–78 U/L 24.0565.29 12.0364.83 ,0.0001
doi:10.1371/journal.pone.0058394.t003
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between the visceral fat and liver via the portal circulation.
Measurements of NEFA in the systemic serum may, therefore,
inaccurately reflect levels in the portal circulation presented to the
liver. In contrast, the TG content of the treated hamster livers
markedly decreased while the serum content did not differ from
that of the controls. Thus, the other mechanism for reducing lipid
levels in NAFLD may be related to decreasing hepatic fatty acid
synthesis and increasing TG export from the liver.
The balance between cholesterol biosynthesis and catabolism is
a critical determinant of serum lipid levels. Following treatment,
the hamsters showed a considerable decrease in serum TC,
although serum FC was unchanged, potentially attributed to a
demand by the liver for accessible cholesterol for VLDL formation
or conversion to bile salts. Because serum LCAT values were
suppressed, it is obvious that there would be a concurrent decrease
in serum HDL, however, serum HDL concentrations in treated
animals remained well within the normal reference range. As
reported before, lowered concentrations of serum HDL translated
into diminished serum EC concentrations [40]. Cholesterol
metabolism is complex, however, such that blood levels might
not always reflect the levels of cholesterol in the liver.
Insulin not only triggers the development of NAFLD but also
worsens its course. We show that fasting serum insulin levels are
closely associated with NAFLD. Our results are also similar to
those of Kelley et al., who found a significant correlation between
plasma-NEFA, insulin sensitivity and NAFLD [39]. Thus, insulin
resistance represents a target for a therapeutic approach.
CRP levels are known to correlate significantly with NAFLD
histological features (degree of steatosis, necro-inflammation and
fibrosis); giving support to the earlier hypothesis that NAFLD is
associated with low-grade systemic inflammation [41]. However,
CRP levels did not differ between the treated and control
hamsters, despite changes in liver fatty infiltration.
NAFLD is also characterized by elevated serum uric acid levels,
an independent predictor of NAFLD since they increase
progressively with the presence and severity of fibrosis [5,42].
Elevated uric acid serum levels in NAFLD is within the context of
insulin resistance since urinary uric acid clearance decreases in
proportion to increases in insulin resistance, leading to an increase
in serum uric acid concentration [42]. In our study, a decrease in
serum uric acid concentrations in the hamsters treated with
microencapsulated L. fermentum ATCC 11976 reflects the corre-
sponding increase in insulin sensitivity and thereby, improvement
in liver histopathology.
ALT is the enzyme known to correlate with liver fat
accumulation and is a biomarker of NAFLD, along with GGT
[29]. Serum levels of ALT and GGT are positively associated with
fasting insulin levels required to maintain normal hepatic glucose
production [43]. In our study, the treatment demonstrated a
normalization of ALT and GGT values, although showing no
particular effect on serum AST levels.
The data from our study suggests the need for well-controlled
trials. No randomized clinical trials have so far been identified
which support or refute probiotics for patients with NAFLD [44].
Preliminary data from two pilot non-randomized studies suggest
that probiotics may be well-tolerated, may improve conventional
liver function tests, and may decrease markers of lipid peroxida-
tion. This probiotic formulation has also shown potential as a
therapeutic for metabolic syndrome [45]. The positive effects of
the microencapsulated L. fermentum ATCC 11976 formulation
treatment on liver tests, histopathology and on parameters of
pathological events related to NAFLD indicate its as a comple-
mentary therapeutic approach in fatty-liver disease patients.
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